Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions mostly support the notion that short-acting opioids are a safe and effective addition to inpatient OUD treatment, with examples like references to reduced discharges and feasibility, and the tone conveys cautious optimism about adopting these methods in clinical settings.
Most discussions highlight support for using short-acting opioids in treatment, reflecting agreement with the article's positive findings.
Participants show moderate interest, as they discuss the safety and implications but do not deeply question the study’s methodology.
Many contributions delve into specific outcomes and clinical implications, indicating active and in-depth engagement.
The discussions suggest that this research could influence clinical practices, especially in inpatient addiction care, though its long-term impact remains to be seen.
The standard of care should be using opioids to treat withdrawal and allow people to get the care they need @especially_APT https://t.co/Oavqv2FHD2
Love attending on inpatient addiction consult service with @BMCAddictionMed Yesterday, we discussed @especially_APT et al's recent paper on the safety and preliminary efficacy of short-acting opioid use in hospitalized patients with OUD: https://t.co/e59IrWhzyG
The next Addiction Medicine Journal Club podcast about short-acting opioid agonists for opioid use disorder in the hospital is coming on Monday. Get the article from @ascp_journal and join the conversation. #addictionmedicine #journalclub #AMJC https://t.co/4dzMbdv0Qs
Short-acting opioid agonist treatment (sOAT) for opioid use disorder (OUD) is safe & effective. LDI Fellows found that sOAT: ⬇️ patient directed discharges (PDDs) ⬆️ length of stay for PPDs ⬆️ rates of medication for OUD. Read more here: https://t.co/ALLbsTKSyQ
@MedFactChecks @LaraAHayes @reverendofdoubt What’s the evidence that dilaudid “perpetuates opioid seeking”? Pubmed search just now on “hydromorphone” and “opioid use disorder” turned up nothing to support that but did find this study showing dilaudid use compatible with management of existing OUD https://t.co/AAD8knX6kT
Important contribution assessing use of oxycodone & PO/IV hydromorphone for w/drawal in 23 hospitalized patients w/ OUD 1 episode of iatrogenic intoxication Increases in MOUD & completing hospitalization More aggressive w/drawal strategies are feasible https://t.co/pCDiblAp87
The Eat Sleep Console care approach shows promise as an effective method for managing neonatal opioid withdrawal syndrome compared to traditional care. This trial involving 1,305 infants indicates significant reductions…
This video provides quick summaries of recent studies including the promising Eat Sleep Console approach for managing neonatal opioid withdrawal syndrome. The method shows a significant reduction in discharge readiness…
21. SOAT for OUD: Short-Acting Opioid Agonists for Opioid Use Disorder Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder. Addict Sci Clin Pract 18, 13 (2023). https://t.co/4dzMbdut0U
RT @ShawnCohen_MD: The standard of care should be using opioids to treat withdrawal and allow people to get the care they need @especially_…
The standard of care should be using opioids to treat withdrawal and allow people to get the care they need @especially_APT https://t.co/Oavqv2FHD2
@MedFactChecks @LaraAHayes @reverendofdoubt What’s the evidence that dilaudid “perpetuates opioid seeking”? Pubmed search just now on “hydromorphone” and “opioid use disorder” turned up nothing to support that but did find this study showing dilaudid use compatible with management of existing OUD https://t.co/AAD8knX6kT
RT @accpPPCprn: In a small, pilot study (n=23) a #PharmD led intervention to provide short acting opioid agonist tx for pts w/ #OUD was ass…
RT @accpPPCprn: In a small, pilot study (n=23) a #PharmD led intervention to provide short acting opioid agonist tx for pts w/ #OUD was ass…
In a small, pilot study (n=23) a #PharmD led intervention to provide short acting opioid agonist tx for pts w/ #OUD was associated w/ ⬇️pt directed discharges (PDD) ⬆️LOS prior to PDD ⬆️MOUD initiation ⬆️naloxone rx'ing https://t.co/QIAdEiy68u
Episode 21 reviews an article about short-acting opioid agonists to treat opioid use disorder in the hospital @ascp_journal. Listen on any podcast app. #opioidusedisorder #AMJC #addictionmedicine #MedEd #journalclub https://t.co/4dzMbdut0U
Ep 21 citation: Thakrar, A.P., Uritsky, T.J., Christopher, C. et al. Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder. Addict Sci Clin Pract 18, 13 (2023). @ascp_journal https://t.co/4dzMbdv0Qs
RT @PennLDI: Short-acting opioid agonist treatment (sOAT) for opioid use disorder (OUD) is safe & effective. LDI Fellows found that sOAT:…
RT @AddictionMedJC: The next Addiction Medicine Journal Club podcast about short-acting opioid agonists for opioid use disorder in the hosp…
The next Addiction Medicine Journal Club podcast about short-acting opioid agonists for opioid use disorder in the hospital is coming on Monday. Get the article from @ascp_journal and join the conversation. #addictionmedicine #journalclub #AMJC https://t.co/4dzMbdv0Qs
Short-acting opioid agonist treatment (sOAT) for opioid use disorder (OUD) is safe & effective. LDI Fellows found that sOAT: ⬇️ patient directed discharges (PDDs) ⬆️ length of stay for PPDs ⬆️ rates of medication for OUD. Read more here: https://t.co/ALLbsTKSyQ
RT @pauljchristine: Love attending on inpatient addiction consult service with @BMCAddictionMed Yesterday, we discussed @especially_APT et…
RT @pauljchristine: Love attending on inpatient addiction consult service with @BMCAddictionMed Yesterday, we discussed @especially_APT et…
RT @pauljchristine: Love attending on inpatient addiction consult service with @BMCAddictionMed Yesterday, we discussed @especially_APT et…
Love attending on inpatient addiction consult service with @BMCAddictionMed Yesterday, we discussed @especially_APT et al's recent paper on the safety and preliminary efficacy of short-acting opioid use in hospitalized patients with OUD: https://t.co/e59IrWhzyG
RT @miriamh_harris: Important contribution assessing use of oxycodone & PO/IV hydromorphone for w/drawal in 23 hospitalized patients w/ OUD…
Important contribution assessing use of oxycodone & PO/IV hydromorphone for w/drawal in 23 hospitalized patients w/ OUD 1 episode of iatrogenic intoxication Increases in MOUD & completing hospitalization More aggressive w/drawal strategies are feasible https://t.co/pCDiblAp87